Bura, V. K., Srivastava, R., Chawla, A. K., Njambe, T. O. E., Khanal, S., Sangal, L., Jha, S., & Bahl, S. (2024). Essential programme on immunization in WHO South-East Asia: A five-decade journey of saving millions of lives & ending diseases. The Indian Journal of Medical Research, 160(3–4), 267.doi: 10.25259/IJMR_1527_2024
Choudhury, S. R., Khandwe, S., & Sharma, M. (2024). Vaccine Diplomacy: Partnering Global Goods. In India, Japan and Beyond: Human Security, Environment, Development, Innovation and Resilience (pp. 145–162). Springer. https://link.springer.com/chapter/10.1007/978-981-97-3282-1_9 (NOT OA)
Debnath, A., Yadav, A., & Lahariya, C. (2025). Vaccine-Preventable Diseases in Pediatric Age Group in India: Recent Resurgence, Implications and Solutions. Indian Journal of Pediatrics, 1-9. (NOT OA)
Gerste, A. K., Majidulla, A., Baidya, A., Georgewill, O., DeLuca, A. N., Pelzer, P. T., Gill, M. M., Jerene, D., Buis, J. S., & Kerkhoff, A. D. (2024). Lessons from a decade of adult vaccine rollout in low-and middle-income countries: A scoping review. Expert Review of Vaccines, 23(1), 688–704. https://doi.org/10.1080/14760584.2024.2375329
Gharpure, R., Longley, A. T., Takamiya, M., Hidle, A., Munyanyi, M., Chawurura, T., Maxwell, L., Mamire, G., Chaora, G., & Chakauya, J. (2024). Typhoid conjugate vaccine perceptions and coverage among children and adults: Findings from a post-campaign coverage survey–Harare, Zimbabwe, 2019. Vaccine, 42(24), 126086. https://doi.org/10.1016/j.vaccine.2024.06.053
Mugisha Emmanuel, K. (2024). Comparative Study of Vaccination Programs against Typhoid Fever in East Africa. https://www.researchgate.net/profile/Kampala-International-University-Ix/publication/
Ndiaye, B. P., Koech, L., Mercer, L., Aponte, J. J., Cisse, B., Riziki, F., Keter, W., Wade, D., Diye, S., & Eaton, N. (n.d.). A Multi-Center, Observer-Blind, Randomized, Phase 3 Study to Evaluate Safety, Non-Inferiority of Multi-Dose and Single-Dose Vial Formulations of EuTCV (Vi-CRM197 Typhoid Conjugate Vaccine) and Lot-to-Lot Consistency of the Immune Response to Multi-Dose Vial Formulation EuTCV in Healthy Participants in Kenya and Senegal. Ndiaye, Birahim Pierre et al. Available at SSRN: https://ssrn.com/abstract=5107101 or http://dx.doi.org/10.2139/ssrn.5107101
Raqib, R. (2024). Bivalent conjugate vaccines for typhoid and paratyphoid fever. The Lancet, 403(10436), 1516–1517. (NOT OA)
Tamrakar, D., Poudel, P., Thapa, P., Singh, S., Khadgi, A., Thapa, S., Tamrakar, R., Shrestha, A., Madhup, S., & Rai, G. K. (2024). Safety and immunogenicity of conjugate vaccine for typhoid (Vi-DT): Finding from an observer-blind, active-controlled, randomized, non-inferiority, phase III clinical trial among healthy volunteers. Human Vaccines & Immunotherapeutics, 20(1), 2301631. https://doi.org/10.1080/21645515.2023.2301631
Van Camp, R. O., & Shorman, M. (2024). Typhoid vaccine. In StatPearls [Internet]. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/sites/books/NBK470571/